IPO registrations (S-1, F-1) · Registrants
Insys Therapeutics, Inc.
- SEC CIK
- 1516479 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2011-03-30, last 2013-05-02; 1 initial registration, 14 amendments
- Outcome
- Final prospectus filed 2013-05-02; declared effective 2013-05-02
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 10220 SOUTH 51ST STREET, SUITE 2, Phoenix, AZ 85044
- EIN
- 51-0327886
- EDGAR entity type
- operating
- Insiders and CEO pay
- Insys Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $8.00–$10.00 per share (S-1/A filed 2013-05-02)
- Final price
- $8.00 per share, within the range (424B4 filed 2013-05-02, an initial public offering)
- Shares sold
- 4,000,000
- Gross proceeds
- $32,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol INSY
- Lead underwriters
- Wells Fargo (1,760,000 shares)
- Syndicate
- JMP Securities (1,760,000); Oppenheimer (480,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: INSYS THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Lobbying client: INSYS THERAPEUTICS, INC. Fuzzy (name and state)
- Lobbying client: INSYS THERAPEUTICS, INC. Fuzzy (name and state)
- SEC filer: Insys Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: John N Kapoor Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 17
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2011-03-30 | S-1 | S-1 (registration) | Insys Therapeutics, Inc. | 0001193125-11-081792 ↗ |
| 2011-05-09 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-11-131195 ↗ |
| 2011-06-06 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-11-158711 ↗ |
| 2011-06-09 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-11-161431 ↗ |
| 2011-06-28 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-11-175190 ↗ |
| 2011-07-15 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-11-189355 ↗ |
| 2011-08-17 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-11-224652 ↗ |
| 2011-08-29 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-11-234589 ↗ |
| 2013-02-27 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-13-078199 ↗ |
| 2013-04-04 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-13-141871 ↗ |
| 2013-04-16 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-13-155510 ↗ |
| 2013-04-18 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-13-160086 ↗ |
| 2013-04-19 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-13-162799 ↗ |
| 2013-04-25 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-13-173614 ↗ |
| 2013-05-02 | S-1/A | S-1/A (amendment) | Insys Therapeutics, Inc. | 0001193125-13-193907 ↗ |
| 2013-05-02 | 424B4 | 424B4 (final prospectus) | Insys Therapeutics, Inc. | 0001193125-13-196437 ↗ |
| 2013-05-02 | EFFECT | EFFECT (declared effective) | Insys Therapeutics, Inc. | 9999999995-13-001368 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-05-02 | S-1/A | registration statement | $8.00–$10.00 | $9.00 | 4,000,000 | $36,000,000 | Nasdaq INSY | 3 | primary document; range, price line, shares headline, proceeds computed, cover names 3 | document ↗ |
| 2013-05-02 | 424B4 | final prospectus | $8.00 | 4,000,000 | $32,000,000 | Nasdaq INSY | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Babich Michael L | Director,Officer | President and CEO; President & CEO | 20 | 2013–2015 | |
| BAKER DARRYL S | Officer | Chief Financial Officer | 15 | 2013–2017 | |
| Dillaha Larry | Officer | Chief Medical Officer | 3 | 2013–2014 | |
| FOURTEAU PATRICK | Director | 21 | 2013–2017 | ||
| JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 | Director,Officer,TenPercentOwner; TenPercentOwner | President & CEO | 15 | 2013–2018 | |
| KAPOOR JOHN N | Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwner | 20 | 2013–2018 | person page Fuzzy | |
| LAPALME PIERRE | Director | 10 | 2013–2019 | ||
| MEYER STEVEN | Director | 1 | 2013 | ||
| STANLEY THEODORE H | Director | 17 | 2013–2017 | ||
| Tambi Brian | Director | 9 | 2013–2018 | ||
| MEYER STEVEN J | Director | 20 | 2013–2019 | ||
| Del Fosse Franc | Officer | General Counsel | 7 | 2014–2017 | |
| Homrich Christopher F | Officer | Sr. VP Operations | 1 | 2014 | |
| BRENNAN DANIEL | Officer | Exec VP & Chf Operations Off. | 2 | 2015–2016 | |
| Vetticaden Santosh | Officer | Interim CEO; Interim CEO and CMO | 3 | 2017 | |
| Motahari Saeed | Director,Officer | President & CEO | 9 | 2017–2019 | |
| Vishnoi Rohit | Director | 6 | 2017–2019 | ||
| Long Andrew G | Director,Officer; Officer | Chief Executive Officer; Chief Financial Officer | 7 | 2017–2019 | |
| Mahboob Vaseem | Director | 4 | 2018–2019 | ||
| Insys Therapeutics, Inc. Voting Trust | TenPercentOwner | 1 | 2018 | ||
| BOHLEN ELIZABETH | Director | 4 | 2018–2019 | ||
| Nance Mark E | Officer | Chief Legal Officer & Gen Cnsl | 4 | 2018–2019 | |
| Vanhove Geertrui | Director | 4 | 2019 | ||
| Housley Andrece | Officer | Chief Financial Officer | 2 | 2019 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | INSYS THERAPEUTICS, INC. | AZ | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Lobbying client | INSYS THERAPEUTICS, INC. | AZ | Federal lobbying (LDA) | name and state |
| Lobbying client | INSYS THERAPEUTICS, INC. | AZ | Federal lobbying (LDA) | name and state |
| Patent assignee | Insys Therapeutics, Inc. | AZ | Patents (USPTO) | name and state |
| SEC filer | Insys Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Insys Therapeutics, Inc. | AZ | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | INSYS THERAPEUTICS, INC. | EIN (EXACT) | ||
| Person page | John N Kapoor | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, AZ first:
- Sibannac, Inc. AZ
- INSYS THERAPEUTICS, INC. AZ
- Cancer Prevention Pharmaceuticals, Inc. AZ
- MIX 1 LIFE, INC. AZ
- HIGH PERFORMANCE BEVERAGES CO. AZ
- LBC Bioscience Inc. AZ
- Dermavant Sciences Ltd AZ
- Journey Medical Corp AZ
- NuvOx Therapeutics, Inc. AZ
- MorphoSys AG 2M
In other datasets, the same topic (Health) in AZ:
- Nonprofit: 22Q CENTRAL (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health